657 patents currently held
77 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
The next term ends in Mar 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
88
Ending by 2030
Mar 2027
Next term end
521
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2036 · High confidence
Also notable
Ends Aug 2041 · High confidence
Also notable
Ends Sep 2027 · High confidence
Also notable
Ends May 2030 · High confidence
Also notable
Ends Oct 2030 · Low confidence
Also notable
Ends Mar 2030 · High confidence
Also notable
Ends Mar 2033 · High confidence
Also notable
Ends Jun 2038 · High confidence
Methods and Kits for Diagnosing, Assessing or Quantitating Drug Use, Drug Abuse and Narcosis, Internuclear Ophthalmoplegia, Attention Deficit Hyperactivity Disorder (ADHD), Chronic Traumatic Encephalopathy, Schizophrenia Spectrum Disorders and Alcohol Consumption
US 11,013,441
Cited by 28 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
System, Method and Computer-Accessible Medium for Real Time Imaging Using a Portable Device
US 11,624,821
Cited by 13 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2041.
Tau Fragments for Immunotherapy
US 8,012,936
Cited by 60 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Method and Apparatus for Providing Input to a Processor, and a Sensor Pad
US 8,766,925
The most cited patent in this portfolio, cited by 230 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2030.
Inhibiting Binding of FGF23 to the Binary Fgfr-Klotho Complex for the Treatment of Hypophosphatemia
US 8,889,621
Cited by 61 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2030.
Tracking and Characterizing Particles with Holographic Video Microscopy
US 9,810,894
Cited by 14 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Chimeric Fibroblast Growth Factor 19 Proteins and Methods of Use
US 9,926,356
Cited by 15 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
System and Method for Ultrasound Analysis
US 11,478,226
Cited by 10 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Formerly held, still cited
Notable
Ends Mar 2033 · High confidence
Cited by 109 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033.
now held by Salk Institute for Biological Studies
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 12 fees due Dec 6 to 30, 2026 · next Dec 6
- 12 fees due Jan 2 to 30, 2027 · next Jan 2
- 12 fees due Feb 4 to 28, 2027 · next Feb 4
- 6 fees due Mar 8 to 26, 2027 · next Mar 8
- 14 fees due Apr 3 to 29, 2027 · next Apr 3
- 8 fees due May 5 to 28, 2027 · next May 5
- 13 fees due Jun 1 to 30, 2027 · next Jun 1
- 12 fees due Jul 2 to 30, 2027 · next Jul 2
- 15 fees due Aug 2 to 23, 2027 · next Aug 2
- 18 fees due Sep 1 to 30, 2027 · next Sep 1
- 16 fees due Oct 2 to 28, 2027 · next Oct 2
- 9 fees due Nov 3 to 19, 2027 · next Nov 3
Recent changes
- Nov 18Assignment recorded on 1 record: Abbadi, Dounia and 1 other to New York University Recorded Nov 18, 2026, executed May 15, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76802, frame 764.
- Nov 13Assignment recorded on 1 record: McDevitt, John T. and 1 other to New York University Recorded Nov 13, 2026, executed Oct 13, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76743, frame 745.
- 13 of the patents on this record were granted since Aug 23, 2026
- 7 terms have ended since Aug 23, 2026
- Oct 28 US 8,871,899 Control of Viral-Host Membrane Fusion with Hydrogen Bond Surrogate-Based Artificial Helices · lapsed on the fee record
- Oct 21 US 8,868,176 Microelectrode-Equipped Subdural Therapeutic Agent Delivery Strip · lapsed on the fee record
- Oct 16 US 10,099,026 System, Apparatus and Method for Supplying Gases · lapsed on the fee record
- Oct 2 US 10,087,243 Compositions and Methods for Phagocyte Delivery of Anti-Staphylococcal Agents · lapsed on the fee record
- Sep 16 US 8,833,368 System and Method for Circuits to Allow CPAP to Provide Zero Pressure · lapsed on the fee record
- Sep 9 US 8,828,413 Peptoid Oligomers, Pharmaceutical Compositions and Methods of Using the Same · lapsed on the fee record
- Aug 26 US 8,815,118 Lock and Key Colloids and Methods of Manufacture · lapsed on the fee record
What they patent
The largest of its 521 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,053,580 | System and Method for Diagnosis and Treatment of a Breathing Pattern of a Patient In force · High confidence | In force | High confidence | |
| US 9,139,643 | Immunotherapy for Clearing Pathological Tau Conformers In force · High confidence | In force | High confidence | |
| US 9,777,056 | Immunotherapy for Clearing Pathological Tau Conformers In force · High confidence | In force | High confidence | |
| US 7,647,098 | System and Method for Prediction of Cognitive Decline In force · High confidence | In force | High confidence | |
| US 9,107,959 | Method for Site-Specific Polyvalent Display on Polymers In force · High confidence | In force | High confidence | |
| US 10,570,442 | Compositions and Methods for Analyzing Immobilized Nucleic Acids In force · High confidence | In force | High confidence | |
| US 7,491,928 | Extended Optical Traps by Shape-Phase Holography In force · High confidence | In force | High confidence | |
| US 8,012,936 | Tau Fragments for Immunotherapy In force · High confidence | In force | High confidence | |
| US 7,896,812 | System and Method for Diagnosis and Treatment of a Breathing Pattern of a Patient In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 8,059,321 | Volumetric Imaging of Holographic Optical Traps In force · High confidence | In force | High confidence |
Also on record, not counted in the 657: 77 patents in force now held by others · 405 patents ended · 297 applications pending · 452 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.